STAT+: 7 key issues we’re watching as RFK Jr. faces a Congressional gauntlet

WASHINGTON — Health secretary Robert F. Kennedy Jr. has a delicate task ahead of him as he heads to Capitol Hill to testify about the fiscal 2027 budget request: Stick to the White House’s script on Make America Healthy Again “wins” while avoiding politically divisive topics like vaccines. 

How he navigates lawmakers’ questions over at least seven hearings will test whether the secretary can stay on message before he embarks on a midterms tour to shore up support for the MAHA movement and the White House’s agenda. 

Thursday’s hearings are Kennedy’s first since a heated Senate health committee appearance in September, where tempers rose as Kennedy defended his firing of Centers for Disease Control and Prevention Director Susan Monarez. 

Continue to STAT+ to read the full story…

Is carbon removal in trouble?

Last week, news outlets reported that Microsoft was pausing carbon removal purchases. It was something of a bombshell.

The thing is, Microsoft is the carbon removal market. The company has single-handedly purchased something like 80% of all contracted carbon removal. If you’re looking for someone to pay you to suck carbon dioxide out of the atmosphere, Microsoft is probably who you’re after.

The company has said that it is not permanently ending its carbon removal purchases (though it didn’t directly answer further questions about this apparent pause). But with this flurry of news, there’s a lot of fear in the industry—so, it’s worth talking about the state of carbon removal, and where Big Tech companies fit in.

Carbon removal aims to reliably pull carbon dioxide out of the atmosphere and permanently store it. There’s a wide range of technologies in this space, including direct air capture (DAC) plants, which usually use some kind of sorbent or solvent to pull carbon dioxide from the air. Another important method is bioenergy with carbon capture and storage (BECCS), in which biomass like trees or waste-derived biofuels are burned for energy, and scrubbing equipment captures the greenhouse gases.

There was a huge boom of interest in carbon removal technologies in the first half of this decade. One UN climate report in 2022 found that nations may need to remove up to 11 billion metric tons of carbon dioxide every year by 2050 to keep warming to 2 °C above preindustrial levels.

One nagging problem is that the economics here have always been tricky. There’s a major potential public good to pulling carbon pollution out of the atmosphere. The question is, Who will pay for it?

So far, the answer has been Microsoft. The company is by far the largest buyer of carbon removal contracts, and it’s the only purchaser that has made megatonne-scale purchases, says Robert Höglund, cofounder of CDR.fyi, ​​a public-benefit corporation that analyzes the carbon removal sector. “Microsoft has had a huge importance, especially for getting large-scale projects off the ground and showing there is demand for large deals,” Höglund said via email.

Microsoft has pledged to become carbon-negative by 2030 and to remove the equivalent of its historic emissions by 2050. Progress on actually cutting emissions has been tough to achieve though—in the company’s latest Environmental Sustainability Report, published in June 2025, it announced emissions had risen by 23.4% since 2020.

On April 10, Heatmap News reported that Microsoft staff had told suppliers and partners that it was pausing future purchases of carbon removal, though it wasn’t clear whether the company would increase support for existing projects, or when purchases might resume. Bloomberg reported a similar story the next day. In one instance, Microsoft employees said that the decision was related to financial considerations, one source told Bloomberg. 

In a statement in response to written questions, Microsoft said that it was not permanently closing its carbon removal program. “At times we may adjust the pace or volume of our carbon removal procurement as we continue to refine our approach toward sustainability goals. Any adjustments we make are part of our disciplined approach—not a change in ambition,” Microsoft Chief Sustainability Officer Melanie Nakagawa said in the statement.

Whatever, exactly, is happening behind the scenes, many in the industry are nervous, says Wil Burns, Co-Director of the Institute for Responsible Carbon Removal at American University. People viewed the company as the foundational supporter of carbon removal, he adds.

“This pause—whether it’s short term or whatever it is—the way it’s been rolled out is extremely irresponsible,” Burns says. The vast majority of firms looking to get carbon removal contracts are probably seeking Microsoft deals. So, while Microsoft has every right to change its plans, the company needs to be open with the industry now, he adds.

“I don’t think you can hold yourself out as the paragon of fostering carbon removal and then treat a nascent industry that disrespectfully,” Burns says.

Carbon removal companies were already in turmoil in the US, particularly because of recent policy shifts: Funding has been cut back, and recent changes at the Environmental Protection Agency were aimed at the government’s ability to target carbon pollution.

Now, if the largest corporate backer is shifting plans or taking a significant pause, things could get rocky.

Depending on the extent of this pause, the industry may need to survive on smaller purchases and hope for support from governments and philanthropy, Höglund says. But for carbon removal to truly scale, we need policymakers to create mandates so that emitters are responsible for either storing the carbon dioxide they produce or paying for it, Burns says.

“Maybe the upside of this is Microsoft has sent a wake-up call, that you just can’t rely on the kindness of strangers to make carbon removal scale.”

This article is from The Spark, MIT Technology Review’s weekly climate newsletter. To receive it in your inbox every Wednesday, sign up here

The quest to measure our relationship with nature

As a movement, environmentalism has been pretty misanthropic. Understandably so—we humans have done some destructive things to the ecosystems around us. In the 21st century, though, mainstream conservation is learning that humans can be a force for good. Foresters are turning to Indigenous burning practices to prevent wildfires. Biologists are realizing that flower-dotted meadows were ancient food-production landscapes that need harvesting or they’ll disappear. And the once endangered peregrine falcon now thrives in part thanks to nesting sites on skyscrapers and abundant urban prey: rats. 

For decades (two, but that counts), I’ve been writing about how humans aren’t metaphysically different from any other species on Earth. Conservation can’t only be about fencing people out of protected areas. A lot of the time the real trick is not to withdraw from “nature” but to get better at being part of it. 

Still, I recognize that living in harmony with nature sounds like a mushy idea. I was therefore stoked to participate in a meeting in Oxford, UK, that sought to build more precise tools to assess human-nonhuman relationships. Scientists have invented lots of measurements of environmental destruction, from parts per million of carbon dioxide to extinction rates to “planetary boundaries.” These have their uses, but they engage people mostly through dread. Why not invent metrics, we thought, that would engage people’s hopes and dreams? 

It was harder than I expected. How do you quantify how good people in any given nation are at living with other Earthlings? Some of the metrics the group proposed seemed to me to be too similar to the older, more adversarial approach. Why tally the agricultural land use per person, for example? Environmentalists have typically seen farms as the opposite of nature, but they’re also potential sites for both edible and inedible biodiversity. Some of us were keen on satellite imagery to calculate things like how close people live to green space. But without local information, you can’t prove that people can actually access that space.

Eventually the 20 or so scientists, authors, and philosophers who met in Oxford settled on three basic questions. First, is nature thriving and accessible to people? We wanted to know if humans could engage with the world around them. Second, is nature being used with care? (Of course, “care” could mean lots of things. Is it just keeping harvests under maximum sustainable yield? Or does it require a completely circular economy?) And third, is nature safeguarded? Again, not easy to assess. But if we could roughly measure each of these three things, the numbers could combine into an overall score for the quality of a human-nature relationship. 

We published our ideas in Nature last year. Though they weren’t perfect, green-space remote sensing and agricultural footprint calculations made the cut. Since then, a team in the United Nations Human Development Office has continued that work, planning to debut a Nature Relationship Index (NRI) later this year alongside the 2026 Human Development Report. Everyone loves a ranked list; we hope countries will want to score well and will compete to rise to the top. 

Pedro Conceição, lead author of the Human Development Report, tells me that he wants the new index to shift how countries see their environmental programs. (He wouldn’t give me spoilers as to the final metrics, but he did tell me that nothing from our Nature paper made it in.) The NRI, Conceição says, will be critical for “challenging this idea that humans are inherent destroyers of nature and that nature is pristine.” Narratives around constraints, limits, and boundaries are polarizing instead of energizing, he says. So the NRI isn’t about how badly we are failing. It speaks to aspirations for a green, abundant world. As we do better, the number goes up—and there is no limit. 

Emma Marris is the author of Wild Souls: Freedom and Flourishing in the Non-Human World.

Opinion: STAT+: The medical AI revolution requires rethinking health care’s architecture

There is a kind of labor at the center of medicine that rarely appears in a chart. It does not sit in the problem list or the billing code. It unfolds in conversation, often quietly, as a patient tries to give shape to something real but not yet defined. They reach for words that are approximate — tired, off, not quite right. The words are not false; they are insufficient. What is being described is not a diagnosis but an experience, and experience resists compression.

In clinical practice, this work lives in a specific place: the history of present illness, or HPI. The HPI reconstructs what has happened to a person over time — how symptoms emerged, evolved, interacted with the physical world, and were perceived. It precedes examination. It precedes testing. It is where medicine begins.

The physician’s task in the HPI is not transcription but interpretation. We ask what was happening when the symptom appeared, whether it arose with exertion or at rest, whether recovery changed, whether confidence shifted before function did. We test meanings against timelines and refine language against physiology, gradually aligning what was said with what can be understood clinically, because the lived details of onset, progression, and functional change materially alter the pre-test probability of disease. A laboratory value or imaging finding does not carry the same meaning in every patient; its significance is conditioned by the story that precedes it.

Continue to STAT+ to read the full story…

The Download: NASA’s nuclear spacecraft and unveiling our AI 10

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

NASA is building the first nuclear reactor-powered interplanetary spacecraft. How will it work? 

Just before Artemis II began its historic slingshot around the moon, NASA revealed an even grander space travel plan. By the end of 2028, the agency aims to fly a nuclear reactor-powered interplanetary spacecraft to Mars. 

A successful mission would herald a new era in spaceflight—and might just give the US the edge in the race against China. But the project remains shrouded in mystery. 

MIT Technology Review picked the brains of nuclear power and propulsion experts to find out how the nuclear-powered spacecraft might work. Here’s what we discovered

—Robin George Andrews 

This story is part of MIT Technology Review Explains, our series untangling the complex, messy world of technology to help you understand what’s coming next. You can read more from the series here. 

Coming soon: our 10 Things That Matter in AI Right Now 

Each year, we compile our 10 Breakthrough Technologies list, featuring our educated predictions for which technologies will change the world. Our 2026 list, however, was harder to wrangle than normal. Why? We had so many worthy AI candidates we couldn’t fit them all in!  

That got us thinking: what if we made an entirely new list all about AI? Before we knew it, we had the beginnings of what we’re calling 10 Things That Matter in AI Right Now.  

On April 21, we’ll unveil the list on stage at our signature AI conference, EmTech AI, and then publish it online later that day. If you want to be among the first to see it, join us at EmTech AI or become a subscriber to livestream the announcement.  

Find out more about the list’s methodology and aims here

—Niall Firth & Amy Nordrum 

MIT Technology Review Narrated: this company is developing gene therapies for muscle growth, erectile dysfunction, and “radical longevity” 

In January, a handful of volunteers were injected with two experimental gene therapies as part of an unusual clinical trial. Its long-term goal? To achieve radical human life extension.  

The therapies are designed to support muscle growth. The company behind them, Unlimited Bio, also plans to trial similar therapies in the scalp (for baldness) and penis (for erectile dysfunction). But some experts are concerned about the plans.  

Find out why the trial has divided opinion

—Jessica Hamzelou 

This is our latest story to be turned into an MIT Technology Review Narrated podcast, which we publish each week on Spotify and Apple Podcasts. Just navigate to MIT Technology Review Narrated on either platform, and follow us to get all our new content as it’s released. 

The must-reads 

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology. 

1 Google, Microsoft, and Meta track users even when they opt out 
According to an independent audit, they may be racking up billions in fines. (404 Media)  
+ How our digital devices put our privacy at risk. (Ars Technica
+ Privacy’s next frontier is AI “memories.” (MIT Technology Review
 
2 OpenAI has a new cybersecurity model—and strategy 
GPT-5.4-Cyber is designed specifically for defensive cybersecurity work. (Reuters $) 
+ OpenAI has joined Anthropic in focusing on cybersecurity recently. (Wired $) 
+ Like Anthopic, its latest model is only available to verified testers. (NYT $) 
+ AI is already making online crimes easier. It could get much worse. (MIT Technology Review

3 Amazon is buying satellite firm Globalstar in a bid to rival Starlink   
The $11.6 billion deal targets the lucrative satellite internet market. (WSJ $)  
+ Apple has chosen Amazon satellites for iPhone. (Ars Technica
 
4 What it’s like to live with an experimental brain implant 
Early BCI users explain what the technology gives—and takes. (IEEE
+ A patient with Neuralink got a boost from generative AI. (MIT Technology Review
 
5 Dozens of AI disease-prediction models were trained on dubious data  
A few might already have been used on patients. (Nature

6 Uber is breaking from its gig economy model to avoid robotaxi disruption  
It’s spending $10 billion to buy thousands of autonomous vehicles. (FT $) 
 
7 xAI is being sued over data center pollution  
Musk’s AI venture stands accused by the NAACP of violating the Clean Air Act. (Engadget
+ No one wants a data center in their backyard. (MIT Technology Review
 
8 Apple could win the AI race without running  
It may reap the rewards of everyone else’s spending. (Axios
 
9 How 4chan set a precedent for AI’s reasoning abilities  
The notorious forum tested a feature called “chain of thought.” (The Atlantic $) 
 
10 The surprising emotional toll of wearing Meta’s AI sunglasses 
Their shortcomings are making users sad. (NYT $) 
 
 

Quote of the day 

“Everything got a whole lot worse once they rolled out AI.” 

—A copywriter tells the Guardian that they’re drowning in “workslop” — AI-generated work that seems polished but has major flaws 

One More Thing 

blocks of frozen carrots and peas

GETTY IMAGES

How refrigeration ruined fresh food 

Bananas may not be chilled in the grocery store, but they’re the ultimate refrigerated fruit. It’s only thanks to a network of thermal control that they’ve become a global commodity. And that salad bag on the shelf? It’s not just a bag but a highly engineered respiratory apparatus. 

According to Nicola Twilley—a contributor to the New Yorker and cohost of the podcast Gastropod—refrigeration has wrecked our food system. Thankfully, there are promising alternative preservation methods.  

Read the full story on her research

—Allison Arieff 

We can still have nice things 

A place for comfort, fun and distraction to brighten up your day. (Got any ideas? Drop me a line.) 

+ Spotify only shows 10 popular songs per artist. This tool lists them all. 
+ These GIF animations are mesmerizing loops of nostalgia. 
+ This site beautifully visualizes Curiosity’s 13 years on Mars. 
+ A retro-futurist designer has turned a NES console into a working synthesizer. 

An inducible base editing platform for cancer functional genomics in vivo

Nature Biotechnology, Published online: 15 April 2026; doi:10.1038/s41587-026-03079-3

We developed a functional genomics platform using a small-molecule-controllable base editor that enables gene editing with reduced cellular toxicity and minimal transcriptional perturbation. The resulting high efficiency of the method potentiates in vivo inducible genetic screening, allowing systematic identification of critical residues in cancer therapeutic targets.

Can psychiatric genetics advance without incorporating a lifecourse perspective?

Psychiatric disorders unfold over the lifecourse, yet genomic studies of these conditions overwhelmingly rely on phenotypes collected at a single time point, often in adulthood. Genome-wide association studies (GWAS) of psychiatric conditions may therefore miss genetic variants with time-varied relevance to etiology, prevention and treatment, such as those that influence trajectories of symptoms and behaviors, age-at-onset, course of treatment response, and co-evolution of comorbidities. With recent advances in longitudinal biobanks and analytic tools, we posit that incorporating a lifecourse perspective in psychiatric genetics will enable critically relevant insights into each of these areas of investigation.

Baseline Mismatch Negativity Amplitude Predicts Direction and Magnitude of Ketamine Effect in Healthy Volunteers — A “Disordinal” Effect

Mismatch negativity (MMN) is a component of the auditory event-related potential (ERP) that is elicited during a passive oddball paradigm where task-irrelevant infrequent deviants are presented in a stream of more frequent standard stimuli. MMN is believed to index a pre-attentive stage of auditory information processing closely linked to N-methyl-D-aspartate receptors (NMDAR) function. Ketamine is thought to act primarily as an NMDAR antagonist, has been used in clinical trials to model the symptoms of schizophrenia and is increasingly used in the clinic to treat depression.

[Editorial] Putting placebo effects in a new light

Placebo effects have puzzled and intrigued researchers for decades but, despite playing an important role in modern trial design and treatment development, they remain relatively mysterious. With the development of new treatments in psychiatry, especially psychedelic-assisted psychotherapy, placebo effects are under the spotlight. In this issue, The Lancet Psychiatry presents two Review articles by Matthew Burke and colleagues on reconceptualising placebo and nocebo effects.